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Cell-based therapies have been studied extensively in the context of transplantation 
tolerance induction. The most successful protocols have relied on transfusion of bone 
marrow prior to the transplantation of a renal allograft. However, it is not clear that stem 
cells found in bone marrow are required in order to render a transplant candidate immu-
nologically tolerant. Accordingly, mesenchymal stem cells, regulatory myeloid cells, T 
regulatory cells, and other cell types are being tested as possible routes to tolerance 
induction, in the absence of donor-derived stem cells. Early data with each of these cell 
types have been encouraging. However, the induction regimen capable of achieving 
consistent tolerance, while avoiding unwanted sided effects, and which is scalable to 
the human patient, has yet to be identified. Here, we present the status of investigations 
of various tolerogenic cell types and the mechanistic rationale for their use in tolerance 
induction protocols.
Keywords: Treg, MDSC, regulatory mechanisms, regulatory myeloid cells, transplantation tolerance, HSCT, 
CD34+ cells
iNTRODUCTiON
Cell-based therapies lie at the root of transplantation tolerance induction protocols. Ray Owen at 
the University of Wisconsin made the early observation that a shared, naturally occurring neonatal 
blood supply was associated with the presence of chimeric red blood cell populations in adult cows 
(1). This, and other, observation prompted Peter Medawar to explore the possibility that donor 
chimerism would allow for acceptance of skin grafts from the same donor through which chimerism 
was established (2, 3). These findings, which led to the Noble Prize in 1960, were exploited by Dr. 
David Sachs (4) and Dr. Sam Strober (5) such that preclinical models (6) for tolerance to solid organ 
transplants could be developed (7–9). These preclinical models led to human clinical trials, which 
have since yielded encouraging results (10, 11).
Indeed, the mechanisms underlying tolerance development are still not clear. Since the 
completion of Medawar’s experiments, investigators have sought to identify the cell populations 
responsible for tolerance induction. Even today, however these cell types and their mechanisms 
remain elusive. Here, we will review some of the cell types, which have demonstrated tolero-
genicity in both experimental and in preclinical models, focusing on the potential for tolerance 
induction in man.
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DONOR BONe MARROw FOR MiXeD 
CHiMeRiSM eSTABLiSHMeNT
Based on the notion that outcomes in human transplantation 
were unacceptable due to the requirement for long-term phar-
macologic immunosuppression, and building on significant 
preclinical data, investigators at Massachusetts General Hospital 
attempted to achieve tolerance in humans. Their approach was 
to first establish lymphohematopoietic chimerism using the 
hematopoietic stem cells of the intended kidney donor, in order 
to establish a milieu where the donor and the recipient existed 
as a “mixed chimera” (10). In their seminal work published in 
the New England Journal of Medicine in 2008, investigators 
described the clinical course of five patients who received con-
ditioning, bone marrow transplantation, and subsequent renal 
transplantation. Transplant recipients were conditioned using 
two preoperative doses of cyclophosphamide, as well as peri-
transplantation anti-CD2, cyclosporine, and thymic irradiation. 
The five patients also underwent bone marrow transplantation 
and renal transplantation. In the group’s original description of 
the bone marrow procurement (11), investigators removed bone 
marrow from the donor’s iliac crest on the day of the transplant 
such that 2.7 × 108 cells/kg were infused into an intended recipi-
ent (11).
As per their initial description, four of the five patients included 
in this study were tolerant, and off all immunosuppression at last 
recorded follow-up (between 2 and 5 years) (10). Interestingly, 
while chimerism was pan-detectable in the first week, four of five 
patients had no detectable chimerism as of day 14, and in the 
remaining one patient only 3.5% chimerism in the granulocyte 
lineage remained until day 21. In this respect, the attempt to 
achieve sustained mixed chimerism failed. Despite this, the 
authors observed excellent clinical results. Given the non-specific 
nature of the bone marrow transplantation, it is difficult to know 
what elements of the cell transplant (bone marrow in this case), 
conditioning regimen, and the organ itself in this early study were 
responsible for long-lasting tolerance. Irrespective of the mecha-
nistic aspects of this initial study, these observations laid down 
the foundation for multiple pursuant studies, which have helped 
to address the tolerogenicity of cell-based transplants aimed at 
tolerance induction (10, 12).
Using donors and recipients who were HLA-matched siblings 
investigators at Stanford University employed a similar cell-based 
tolerance induction protocol for renal transplant recipients. Also 
published in the New England Journal of Medicine, Scandling 
et al. presented a series of 10 patients who underwent treatment 
with anti-thymocyte globulin, cyclosporine, and total lymphoid 
irradiation. Differing somewhat from the Massachusetts General 
Hospital (MGH) experience, an immunomagnetic bead column 
was used to enrich the bone marrow transplant for CD34+ hemat-
opoietic stem cells. The bone marrow donor was first mobilized 
with a 5-day course of subcutaneous G-CSF 6  weeks prior to 
procurement. Their patient then received 8 × 106 CD34+ hemat-
opoietic stem cells in addition to 1 × 106 CD3+ lymphocytes. The 
cell transplant was cryopreserved and administered on day 14, 
following completion of total lymphoid irradiation (13, 14). In 
more recent publications, the Stanford University group has 
shown that 8 of 15 patients completing the tolerance induction 
protocol were chimeric for 6 months or greater and successfully 
weaned from immunosuppression (14). Only four patients were 
not withdrawn from immunosuppression secondary to underly-
ing disease or episodes or rejection (14). Thus, in a well-matched 
cohort, both sustained mixed chimerism and renal transplanta-
tion tolerance could be achieved using this approach.
A third group at Northwestern University has successfully 
implemented human tolerance induction protocols using a dis-
tinct, yet similar cell-based protocol. Again, T cell depletion was 
utilized, however with two doses of alemtuzumab (anti-CD52) 
(15, 16). Tacrolimus in addition to mycophenolate mofetil was 
initiated at the time of transplantation. The first of four bone 
marrow transfusions obtained via iliac crest aspiration were given 
on posttransplantation day 5, followed by repeat transfusions at 
months 3, 6, and 9 (16). Bone marrow donors were mobilized with 
Neuopogen prior to donation, and bone marrow infusions were 
enriched for CD34+ hematopoietic stem cells. Encouragingly, 
five of the institution’s first eight patients were stably tolerant 
of their renal allografts at 1-year posttransplantation (16). The 
Northwestern group has also employed the use of “facilitator 
cells” to augment the chimeric state and tolerogenic milieu, 
although the details of these CD8+ non-T cell types are largely 
unknown as they are considered proprietary (15, 17).
Taken together, it is clear that bone marrow infusions, likely 
through the action of CD34+ hematopoietic stem cells can lead 
to tolerance induction in humans. Importantly, and consistent 
with the initial observations of Starzl and Demetris (18), it may 
not be absolutely necessary for a high-level of chimerism to last 
indefinitely, in order for the transplanted graft to remain tolerated 
(8, 10, 12).
In fact, the loss of chimerism (>1% donor cells) may coincide 
with a totally chimerism-free state, wherein tolerance is sustained 
solely by anergy and immunoregulation induced by the kidney 
graft parenchyma, as suggested by Sachs et al. (7, 8) Alternatively, 
the loss of macro-chimerism may coincide with the onset of 
micro-chimerism (<0.1% donor cells), a setting in which the 
“two-way” model of transplant tolerance, as proposed by Starzl 
and Demetris, is sustained (18, 19). Although Starzl’s theory was 
based on mutual HvG/GvH reactions, and not on Regulatory 
T  cells, a recent report indicates that Treg cells induced in the 
offspring during the transient chimerism stage of pregnancy are 
maintained by constant contact with rare maternal hematopoetic 
cells, indicating a key role for maternal microchimerism in toler-
ance (20).
In addition to the above descriptions of chimerism establish-
ment, exciting new reports have promulgated an alternative 
hypothesis underlying the mechanisms of tolerance induction 
through bone marrow infusion. Authors have shown that CD34+ 
monocytes are capable of inducting apoptosis of donor reactive 
T cells, and that through Treg expansion, this leads to tolerance. 
Regardless of the underlying mechanisms, immune tolerance 
through bone marrow infusion has proven efficacy in humans. 
However, additional potentially less morbid cell-based therapies 
are in development as well (21).
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MeSeNCHYMAL STeM CeLLS
Adapted from bone-marrow transplantation efforts to reduce 
the rate of bone-marrow graft failure following haplo-identical 
transplantation, mesenchymal stem cells may be capable of toler-
ance induction (22, 23). Pluripotent mesenchymal stem cells are 
naturally occurring and exist within the bone marrow (24–28). 
Mesenchymal stem cells are precursors to bone, fat, and other 
connective tissues. Additionally, however, mesenchymal stem 
cells have been shown to support normal hematopoiesis and 
to demonstrate immunosuppressive qualities (22, 25, 27, 28). 
Mesenchymal stem cells can rapidly expand ex vivo, yet they do 
not lose potential to differentiate into multiple cell types (23, 24, 
28). Partially explaining augmentation of haplo-identical bone-
marrow transplantation, mesenchymal stem cells also assist with 
engraftment of hematopoietic stem cells (23).
It has been hypothesized that mesenchymal stem cells partly 
explain the tolerogenic nature of bone marrow transplantation for 
tolerance induction. Accordingly, small and large animal models 
of attempted tolerance induction using these cells have been 
studied (23). In a rodent model of heterotopic heart transplanta-
tion, investigators observed that rapamycin alone led to rejection 
of haplo-mismatched cardiac grafts by 3  weeks. In contrast, 
mesenchymal stem cell infusion as monotherapy inhibited acute 
rejection, and when infusion of mesenchymal stem cells was 
coadministered with rapamycin, recipients enjoyed long-term, 
and rejection-free graft survival (23). Recipients of mesenchymal 
stem cell infusion also displayed minimal antibody production. 
Investigators observed deposition of mesenchymal stem cells into 
the cardiac grafts, as well as increased number of FoxP3+ T regula-
tory cells (23). Mechanistically, authors offered that the intra-graft 
mesenchymal stem cells might (1) protect the donor heart from 
exposure of alloantigens, and (2) provide local immunomodula-
tion for alloreactive T cell clones (23). While mesenchymal stem 
cells are certainly immunosuppressive, infusion of mesenchymal 
stem cells alone was insufficient to overcome the alloreactive host 
responses, suggesting that other factors intrinsic to the bone mar-
row (beyond mesenchymal stem cells) are potentially required for 
tolerance induction. Corroborating these findings, other authors 
have shown that mesenchymal stem cell infusions prolonged 
baboon skin graft survival (29) as well as survival of liver, kidney, 
and heart allografts in small animal models (23, 30–32).
The immunomodulatory effects of mesenchymal stem cells 
have been studied and their interplay with other immunological 
cell types has begun to be characterized (25–27). Indeed, authors 
have recently shown that the differential efficacy of mesenchymal 
stem cells is based on the cell source, suggesting that not all mes-
enchymal stem cells are created equally (33). While a complete 
understanding of the responsible mechanisms is incomplete, 
there is a clear upregulation of FoxP3+ Regulatory T cells result-
ing from mesenchymal stem infusion (34). In addition, the sup-
pressive functions of mesenchymal stem cells are thought to be 
mediated by both cell-to-cell contact as well as through the action 
of soluble factors (35). Additionally, mesenchymal stem cells have 
been shown to down regulate MHC class II and costimulatory 
molecules, resulting expansion of regulatory dendritic cells and 
impaired alloreactive T cell homing, respectively (30, 35–37). 
Perhaps important to clinical applications, recent reports sug-
gest that the timing of mesenchymal stem cell administration is 
important to graft survival. In addition, the immunosuppressive 
effects of mesenchymal stem cells have been shown to overcome 
the effects of graft versus host disease (GVHD) in man (38, 39). 
Indeed, in a rodent renal tolerance model, when mesenchymal 
stem cells were infused after kidney transplantation (versus 
prior), graft dysfunction and neutrophilic infiltration were 
observed within the graft. Unfortunately, however, at present it 
appears that the lifespan of mesenchymal stems cells is limited 
(28, 40). In contrast, significant graft survival prolongation was 
observed with the mesenchymal stem cell administration pre-
ceded organ transplantation (36). More recently, human studies 
of mesenchymal stem cell administration in living donor kidney 
transplantation demonstrated reduced doses of tacrolimus were 
required for those receiving cell therapy in addition to calcineurin 
inhibition (41), and improved graft function at 1 year. In 2015, 
investigators published of a human pilot study of renal trans-
plantation, in which pre- and posttransplantation administration 
of autologous mesenchymal stem cells was found to be not 
only safe, but the infusion lead to upregulation of Tregulatory 
cells in recipients (42). Taken together, mesenchymal stem cells 
seem capable of significant immunosuppression; however, the 
immunosuppressive effects appear incomplete, suggesting that 
additional elements need to be addressed for tolerance induction 
via mesenchymal stem cell adminsitration (41, 43).
EX VIVO eXPANDeD ReGULATORY 
T CeLLS
Regulatory T Cells
Regulatory T cells are perhaps the most widely discussed cell type 
with regard to tolerance induction and their biology has driven 
much of the recent research in transplantation tolerance (12, 
13, 44–50). Regulatory T cells, of which there are many subsets, 
are naturally occurring, and are required for self-tolerance. 
Additionally, Regulatory T  cells have been implicated in the 
immunosuppressive mechanisms described for each of the cell 
types presented in this manuscript (51–60). While some investi-
gators have reasoned that Regulatory T cells may be a marker of 
tolerance rather than the unifying mechanism by which tolerance 
to organ transplants is mediated, few will argue with the idea that 
Regulatory T cells are critical to the success of tolerance protocols. 
Accordingly, recent data show that microchimerism may itself 
sustain antigen-specific Regulatory T cells in a mouse model (20). 
Indeed, the hypothesis that Regulatory T cells represent a marker 
of tolerance is gaining traction among the tolerance community 
(20).
From the standpoint of cell-based tolerance induction 
protocols, Regulatory T  cells can be expanded ex vivo and 
administered exogenously, or transplanted as part of a tolerated 
graft (intra-graft Regulatory T  cells; for caveats, see Section 
“Intragraft Regulatory T cells”). Endogenous Regulatory T cells 
have been studied extensively and are conventionally defined 
as thymic derived (tRegulatory T cells) or peripherally derived 
(pRegulatory T  cells). tRegulatory T  cells and pRegulatory 
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T cells can be distinguished by different cell surface identifiers 
(CD39, CTLA-4, etc.) and by the soluble factors produced (IL-35, 
etc.). Notably, both tRegulatory T cells and pRegulatory T cells 
populations express intranuclear FoxP3, a transcription factor 
thought to be the most specific marker for Regulatory T  cells 
(61–63). Additionally, helios, a member of the Ikaros family of 
transcription factors, has been shown to distinguish thymic from 
peripheral Regulatory T cells (64). While helios is expressed in 
100% of thymocytes, naive rodent and human FoxP3 cells T cells 
generated peripherally via TCR stimulation failed to express 
helios (64). While the exact function of FoxP3 itself it not fully 
known, it is thought to downregulate the nuclear factor of acti-
vated T cells (NFAT) (62).
The mechanisms of Regulatory T cells have been extensively 
studied and recently reviewed (65). There are four primary 
actions, which are thought to mediate the inhibitory function of 
Regulatory T cells: (1) release of soluble, inhibitory factors, (2) 
cytolysis, (3) metabolic dysregulation, and (4) manipulation of 
the function of dendritic cells (65). The soluble factors IL-10 and 
TGF-beta have garnered significant interest in the Treg literature 
as the primary cytokines by which negative inhibition is mediated 
(66, 67). However, it is unclear if the cytokine profile for tRegula-
tory T cells and pRegulatory T cells is similar (65, 68). Building 
data from our laboratory and others have also suggested that 
IL-35 (Tomita et al., unpublished data) (69). It is also becoming 
clear that like natural killer cells and like cytotoxic T cells (CD8+), 
and regulatory T cells inhibit anti-donor responses via cytolysis 
through the activity of perforin and granzyme A (65, 70). While 
not widely discussed as a primary Treg function, regulatory 
T cells are also known to deplete IL-2 from the microenviron-
ment, resulting in metabolic dysregulation of target T cells (71, 
72). The interaction of Regulatory T cells and dendritic cells is 
bidirectional. Below in the review, we will discuss tolerogenic 
monocytes, which are upstream to Regulatory T cells, however 
Regulatory T cells themselves may also affect the maturation of 
suppressive monocytes through the action of CTLA-4 and other 
inhibitory signals (65, 73).
Given their known suppressive role in  vivo following 
protocols of tolerance induction, much interest has focused 
on ex vivo expansion of Regulatory T  cells such that subse-
quent administration might lead to tolerance induction. 
Regulatory T  cells may be generated (induced Regulatory 
T cells or iRegulatory T cells) ex vivo, in the presence of IL-2 
and TGF-beta (61, 67). Indeed preclinical and recent human 
trials have demonstrated that massive expansion of Regulatory 
T cells is possible, ex vivo. For such expansions, costimulation 
of purified Regulatory T  cells (CD4+CD25+CD127lo) with 
CD28 in the presence of rapamycin has been associated with 
a 1000-fold increase in Regulatory T cells over approximately 
3  weeks (74, 75). These protocols were extended to humans 
for the treatment of GVHD, with encouraging results. Notably, 
rapid expansion of Regulatory T cells ex vivo is associated with 
reduction is Regulatory T  cells’ suppressive qualities, despite 
the production of FoxP3 (74, 75). Similar expansion rates 
(also using CD28 costimulation) and findings were observed 
in human studies of autoimmune hepatitis (76, 77) and other 
autoimmune diseases (51).
Ex vivo expansion of Regulatory T cells has been attempted in 
both preclinical and clinical settings (78, 79). In a mouse model, 
investigators were able to expand antigen-specific CD4+CD25+ 
Regulatory T cells using antigen-primed, immature dendritic cells 
(79). Authors then adoptively transferred these antigen-specific 
Regulatory T  cells into skin-graft recipients (78). Investigators 
found that CFSE-labeled Regulatory T  cells migrated into the 
transplanted grafts, that survival was prolonged (stable appear-
ance and hear growth at >150 days), and that animals displayed 
evidence of transplantation tolerance (78). In a preclinical human-
ized mouse model of skin transplantation, investigators recently 
demonstrated that exogenous antigen-specific Treg administra-
tion significantly prolonged skin-graft survival. Importantly, the 
Treg expansion protocol utilizing CD69 and CD71 enrichment 
was thought to be scalable to the clinic (80). In a phase 1 2011 
study, Regulatory T cells were expanded ex vivo from umbilical 
cord blood and administered to partially HLA-matched patients 
with hematologic malignancy. Not only did this prove to be 
safe but also it provided preliminary evidence that recipients of 
these Regulatory T cells had decreased risk of acute GVHD (59). 
Another 2011 study was able to show that Regulatory T  cells 
coinfused with conventional T  cells prevented GVHD without 
the use of posttransplant immunosuppressive therapy (60).
According to the National Institutes of Health, there are four 
open-active trials and one closed-active trial utilizing the infu-
sion of ex vivo generated Regulatory T cells. A European group 
focused on cellular immunotherapy in organ transplantation 
has a phase 2 study in process in which autologous Regulatory 
T cells are removed from living donor renal transplant recipients, 
and after 5 days of expansion, they are reinfused into the recipi-
ent. In a second approved human trial, through the University 
of Minnesota, investigators are using autologous, donor 
alloantigen-specific Regulatory T cells produced from expanded 
Regulatory T  cells obtained from pre-liver transplant patients. 
The Regulatory T cells are then infused back into the recipient 
at regular intervals with the goal of achieving tolerance. A group 
from the University of California San Francisco is using ex vivo 
generated and expanded Regulatory T  cells to assess the effect 
on beta cell function and the autoimmune response in type 1 
diabetes. Another phase 1 trial is investigating the safety, toler-
ability, and effect of three different doses of ex vivo expanded 
polyclonal Regulatory T cells in the cutaneous manifestation of 
patients affected with lupus erythematosus. Another phase 1 trial 
is using ex vivo Regulatory T  cells for the prevention of acute 
GVHD in patients with hematological malignancies following 
hematopoietic stem cell transplantation. Another group from the 
University of California San Francisco is investigating the role of 
ex vivo expanded Regulatory T cells as a therapy for subclinical 
inflammation in kidney transplant patients.
iNTRAGRAFT ReGULATORY T CeLLS
It is widely accepted that immunomodulatory cell types home to 
areas of acute inflammation, and that these cell types establish a 
local, tolerogenic milieu (at least partly) through direct cell-to-
cell interaction (44, 46, 48, 81–86). In a miniature swine animal 
model of MHC class-I disparate tolerance induction, authors 
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have shown that a short course of calcineurin inhibition via 
cyclosporine leads to robust, long-lasting tolerance, which is not 
abrogated by infusion of pro-inflammatory cytokines, removal 
of the tolerated graft, or leukapheresis of peripheral T regulatory 
cells (44–46, 82, 87–89). Indeed, only when the tolerated kidney 
was removed for more than 3  months in this model, during 
which time the animal is kept alive by renal-transplantation with 
a recipient-matched kidney, did tolerance begin to wane (45, 90). 
These data are supported by mechanistic data in small animal 
models of heart transplantation (91). This abrogation of tolerance 
was hastened by sensitization with donor-derived peptide (45).
Given that Regulatory T  cells are known to mediate both 
tolerance induction and tolerance maintenance in the model, 
investigators hypothesized that adoptive transfer of recipient-
derived Regulatory T  cells (both peripherally and from within 
the graft) could lead to stable tolerance in a naive recipient (44, 
46). While adoptive transfer of leukapheresed Regulatory T cells 
alone did not lead to tolerance induction, transplantation of the 
tolerated kidney (with or without peripheral Treg infusion) did 
lead to stable tolerance in the naive recipient (44). These data 
suggested that the intra-graft regulatory components, widely 
thought to be CD4+CD25+FoxP3+ Regulatory T  cells, were 
capable of overcoming the intrinsic alloreactive responses from 
the naive recipient (86, 88, 89, 92). In this way, adoptive transfer 
of intra-graft Regulatory T cells is thought to be capable of toler-
ance induction (46). While important mechanistically, this model 
itself has little direct applicability to the clinic. However, these 
data strongly support the notion that tolerance is mediated by 
immunoregulatory cells and that, were these cells clinically avail-
able, transplantation tolerance might be readily achieved. There 
are questions surrounding this cell population. For example, it 
is unclear what percentage of intagraft cells are antigen specific, 
in contrast to tRegulatory T cells and pRegulatory T cells. If, for 
example, intragraft Regulatory T cells are enriched with donor-
specific Regulatory T  cells, these mechanisms by which this 
occurs might be exploited and extrapolated to the clinic.
CD40L(CD154)/CD40 is one of the key costimulatory 
mechanisms required for T-cell activation. CD40L(CD154) 
monoclonal antibody has used as a blocker of this costimulation 
pathway. After the clinical failure of CD40L(CD154) blockade 
in humans and non-human primates (NHP), the interest in the 
CD40L(CD154)/CD40 axis has reemerged due to promising 
results with CD40 blockade. In mice, donor-specific transfusion 
(DST) plus CD40L(CD154) blockade is a standard and successful 
protocol to induce donor-specific transplant tolerance, involving 
apoptosis, acquisition of regulatory cells, and suppression of 
proliferation of effector cells (93, 94).
Abbas and colleagues (95) have shown that there can be many 
resident T  cells in transplanted organs and tissues, including 
both pro-inflammatory memory T cells and memory Regulatory 
T  cells. On day 30–40 after resolution of an inflammatory 
response in the skin, activated T cells, which had migrated from 
central lymphoid tissue, were maintained in the target tissue, thus 
developing “Treg memory” to that tissue. This period roughly 
corresponds to the kinetics of development of allo-specific, linked 
suppression responses observed in DST and CD40 blockade 
tolerization model (Tomita et  al., submitted). Mechanistically, 
it is thought that anti-CD40L(CD154) leads to rapid changes 
in lymph node architecture and to the migration of Regulatory 
T cells and T effector cells through high-endothelial venules (96).
While capable of tolerance induction, the kinetics of periph-
eral allo-specific regulatory T memory cells into tissues (other 
than the lymphoid tissue) are unknown. In mice, approximately 
5 weeks after DST and CD40 blockade, treatment was sufficient 
for allo-specific regulation to manifest itself in both the lymphoid 
tissue and the non-lymphoid organ (liver) (Tomita et al., submit-
ted). The regulatory phenomenon was mediated by TGF-beta 
and IL-35, and the proportion of regulatory cytokine-producing 
CD4 T cells increased in lymphoid tissues and liver over time. 
However, TGF-beta producing and IL-35 producing cells had 
different migratory kinetics.
Whether Regulatory T cells (intra-graft or otherwise) induce 
tolerance directly or by virtue of facilitating other cell populations 
is unclear. Indeed, recently groups have reported that plasmacy-
toid dendritic cells are capable of facilitating hematopoietic cell 
engraftment. Below, we will address several addition cell popula-
tions, which may induce tolerance; however, it remains unclear if 
their function is by virtue of facilitation or by direct tolerogenic 
effects (17).
ReGULATORY MYeLOiD CeLLS
Myeloid cells derive from hematopoietic stem cells. Rather than a 
rigidly defined group of progressively matured cell types, myeloid 
cells are better conceptualized as a network of cells, which can 
differentiate into various subsets (52). Regulatory myeloid 
cells (RMCs) include three broad classes of cells: regulatory 
macrophages (Mregs), dendritic regulatory cells (DCregs), and 
myeloid derived regulatory cells. In vitro models using human 
cells demonstrate each class of RMC can be generated from 
peripheral blood mononuclear cells (PBMCs) (58). However, the 
signals required for differentiation into each cell type (Mreg vs. 
DCreg vs. MDSC) are different. For example, in vitro differen-
tiation of human PBMC into Mregs is facilitated by interferon 
gamma and macrophage colony stimulating factor (M-CSF). In 
contrast, expansion of DCregs from human PBMC is thought to 
require granulocyte/monocyte (GM)-CSF in addition to IL-4, 
IL-10, and TGF-beta plus other potentially tolerogenic factors. 
Lastly, MDSCs differentiation from PBMCs is supported by 
G-CSF and GM-CSF, and activation of MDSC requires IL-1, IL-6, 
and other pro-inflammatory factors (58).
Regulatory myeloid cells have elicited significant interest 
from the transplantation tolerance community, and clinical 
studies involving the use of DCregs as well as Mregs have been 
undertaken.
Regulatory Macrophages
Regulatory macrophages are a uniquely characterized group of 
cells expressing a profile of distinct group of cellular markers. 
They possess a novel gene-expression profile that is different 
from monocytes, monocyte-derived DCs, resting macrophages, 
IFN-gamma stimulated macrophages, and M-1, M2a-, M2b-, 
and M2c-polarized macrophages (97). They are derived from 
peripherally isolated CD14+ monocytes that are cultured for 
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7 days while exposed to M-CSF, 10% human serum, and a 24-h 
pulse of IFN-gamma (98). The mechanisms by which these cells 
work have been investigated in both mice and humans. Mouse 
Mregs have been shown to inhibit T cell activity in  vitro via 
inducible nitric oxide synthase (iNOS). In addition, Mregs delete 
cocultured allogeneic T cells via phagocytosis. In small animal 
models, T cells that avoided phagocytosis developed an impaired 
ability to secrete IL-2 and IFN-gamma (99). Human Mregs have 
been found to be potently suppressive of T cell proliferation 
via IFN-gamma induced indoleamine 2,3-dioxygenase (IDO) 
activity and contact-dependent deletion of activated T  cells 
(100). Riquelme and colleagues were able to demonstrate that a 
one-time intravenous dose of donor-derived Mregs given 8 days 
before cardiac transplantation in mice was able to significantly 
prolong allograft survival in immunocompetent recipients. The 
graft survival was antigen-specific as graft survival. Indeed, 
recipient Mreg infusions (and third party controls) yielded no 
survival prolongation (99). This mechanism appeared to be 
iNOS independent.
Regulatory macrophages are an attractive option for cell-
based tolerance induction in human recipients. A number 
of clinical trials have begun investigating this approach. The 
TAIC-I clinical trial was a single center, open-label single-arm 
study to assess the safety and tolerability of administering Mreg 
cell preparations to renal transplant recipients. A total of 12 
patients receiving their first renal transplant from a decreased 
donor were enrolled and infused with 0.9–5.0 ×  108 cells via 
central venous access 5  days after transplantation. Mregs 
were isolated by culturing donor splenic mononuclear cells in 
M-CSF and stimulation with IFN-gamma. There were no acute 
or later observed adverse reactions, providing initial clinical 
evidence that this is a safe therapy (101). A subsequent trial, 
TAIC-II, assessed the safety and efficacy of administering Mreg 
cell preparations to recipients of living-donor renal transplants. 
A total of 5 living-related kidney transplant recipients were 
infused with 1.4–5.9 ×  108 cells, received induction therapy 
with anti-thymocyte globulin, in addition to steroid and tac-
rolimus (trough levels of 8–12  ng/ml). Mregs were obtained 
by culturing donor pPBMCs in M-CSF and stimulation with 
IFN-gamma followed by coculture with recipient PBMCs. No 
acute reactions occurred. Steroids were weaned by 8  weeks 
posttransplant, and tacrolimus was decreased to 5–8  ng/ml. 
Four patients were successfully transferred to this dose of tac-
rolimus therapy, with no rejection occurring in two patients. 
Tacrolimus levels were further weaned to <2  ng/ml, and one 
patient experienced rejection at 36 weeks. Following cessation 
of immunosuppression, two patients experienced rejection at 
2 and 34 weeks postcessation (102). Another patient that did 
not qualify for the TAIC-II trial because of measurable levels 
of anti-donor HLA antibodies was described by Hutchinson 
and colleagues. The patient received a presensitized living-
related renal transplant. The patient was infused with 4.8 × 109 
Mregs 17 days prior to transplant, which were isolated via the 
same protocol as the TAIC-II study. The patient was stable at 
27 months posttransplant and interestingly was no longer posi-
tive for the anti-donor HLA antibodies. Serological screening 
determined that the patient remained hepatitis A virus positive 
(was positive before transplant) suggesting that this was a 
specific effect of Mreg treatment (103).
Since these two trials, Hutchinson and colleagues have refined 
their Mreg purification and treated two living-donor kidney 
transplant recipients. The first patient received a single HLA-B 
and DR mismatched-related kidney from her mother and 8 × 106 
donor-derived Mregs via central venous infusion 6 days prior to 
transplant. Azathioprine, steroids, and tacrolimus were started at 
the time of transplantation and at 3 years posttransplant, and the 
patient was stable with no signs of rejection demonstrated via 
biopsy while maintaining tacrolimus trough levels of 4–5 ng/ml. 
The second patient received a fully mismatched kidney from a 
living unrelated donor and 7.1 × 106 Mregs 7 days prior to trans-
plant. Azathioprine, steroids, and tacrolimus were started during 
transplantation. At 3 years posttransplant, the patient was stable 
with no signs of rejection via biopsy and was being maintained on 
tacrolimus with a trough level of 2.7 ng/ml (100). Taken together, 
preliminary evidence suggests that Mreg treatment preoperatively 
in renal transplant patients is safe, and further work needs to be 
done in humans to describe its effectiveness. The ONE Study is 
currently aiming to develop an array of cellular based therapies, 
one of which is Mregs, in order to achieve immunologic tolerance 
in transplant patients (104).
Dendritic Regulatory Cells
Dendritic regulatory cells have been reviewed in detail recently 
(51, 97, 105). In one early human study of DCregs, authors 
observed that in response to injection of 2 × 106 immature DCregs, 
antigen-specific Regulatory T cells were developed, and CD8+ T 
cell effector function was inhibited (58, 106, 107). Additionally, a 
more recent study of DCregs was undertaken in type I diabetes, 
for the purposes of self-tolerance (overcome autoimmunity). 
Authors administered 10 million cells intra-abdominally every 
2 weeks for a total of four injections. DCreg injections were not 
associated with adverse reactions. Perhaps important, investiga-
tors did observe an increase in the percentage of suppressive 
B220+ B cells, which may help suppress autoimmunity in type 1 
diabetes (108).
MDSCs
MDSCs are a heterogeneous, immature population of mono-
cytic- (mMDSCs) and granulocytic (gMDSCs)-derived cells 
that work to negatively regulate the immune system. MDSCs 
are naturally occurring, and are expanded during times of 
stress and inflammation (109). Much of what we know about 
MDSCs comes from cancer biology and the mechanisms by 
which MDSC-mediated immunosuppression occurs are being 
investigated. MDSC-mediated immunosuppression occurs 
through several known mechanisms. Primarily MDSCs have 
been found to express high levels of arginase-1 (produces 
urea and l-ornithine from l-arginine) and iNOS (generates 
NO), which have a well-established role in the suppression of 
T cell function (110, 111). By expressing arginase-1, MDSCs 
deplete local l-arginine levels of arginine, which is required 
by lymphocytes. In addition, MDSCs increase NO production. 
Arginase-1 dependent l-arginine depletion and NO production 
diminish the ability of T cells to proliferate and express MHC 
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class II as well as inducing T cell apoptosis (112–116). MDSCs 
have also been shown to elicit immunosuppressive effects 
through the production of reactive oxygen species (ROS) 
and peroxynitrite (117–121). In the case of the latter, the 
peptide-MHC structure is altered, weakening the peptide’s 
immunogenicity (109). Likely important for potential toler-
ance induction, MDSCs have been found (in the presence of 
IFN-gamma and IL-10) to induce de novo development of 
FoxP3+ Regulatory T cells (116, 122). MDSCs are capable 
of inducing the proliferation of existing Regulatory T cells 
and that depletion of Trges impairs the ability of MDSCs 
to accumulate (116, 123, 124). The mechanisms by which 
MDSCs contribute to immune tolerance is multifactorial, 
involves other cell types and is likely to be subset dependent 
as well (109, 125).
With regard to MDSCs and solid organ transplantation, 
Vanhove and colleagues have shown in a kidney transplant 
rat model that immune tolerance was induced via anti-CD28 
and that MDSCs accumulated within the allograft (126, 127). 
In vitro, the MDSCs were able to induce contact-dependent 
apoptosis of T cells, which induced the expression of iNOS in 
the MDSCs. The MDSCs were also found to have a minimal 
effect on Regulatory T cells that failed to induce iNOS in the 
MDSCs. These results highlight the cross-talk between these 
two cell types in immune tolerance. Lu et  al. demonstrated 
that transplantation of hepatic stellate cells into diabetic mice 
induced MDSCs. In addition, these MDSCs were associated 
with increased levels of iNOS and Arg-1 as well as CD4+ and 
CD8+ T cell suppression. The same group also demonstrated 
that with cotransplantation of 2.5 × 106 MDSCs and islet cells 
into diabetic mice, the survival of the islet cell allograft was 
significantly prolonged (128). In vitro and in vivo data both 
supported the necessity of the B7–H1 interaction for induc-
tion of Regulatory T cells involved in this process. Another 
study using repeated injections of LPS to induce MDSCs 
and evoke tolerance reported prolonged allograft survival 
through T cell suppression via a heme oxygenase-1 dependent 
pathway (129). This group was unable to reverse the T cell 
suppression by neutralizing iNOS or Arg-1, perhaps high-
lighting another immunomodulatory mechanism of MDSCs. 
Recently, Thomson and colleagues from the University of 
Pittsburgh showed that MDSCs can suppress T cell prolifera-
tion and cytokine secretion in non-NHP in vivo (130). This 
has raised the possibility of scaling these MDSC models to the 
NHP, and perhaps humans as well. In summary, much work 
is being done to uncover the mechanisms by which MDSCs 
contribute to establishing immune tolerance and the potential 
for use as a cellular based therapy is promising.
Regarding the potential for MDSCs in human transplanta-
tion, studies are lacking. Encouragingly, recent hematology 
data suggesting that MDCSs may control GVHD, and addi-
tional data demonstrating that MDSCs are upregulated after 
transplantation have highlighted MDSCs as a possible avenue 
to tolerance in humans (131). In a recent review, authors 
suggested that excitement for MDSCs in tolerance should be 
tempered until additional MDSC phenotyping can be per-
formed. Indeed, it is not yet clear if the immunosuppressive 
effects of MDSCs are specific vs. non-specific, and it is not 
yet clear if MDSCs would need to be used synergistically with 
other therapies (127, 131).
B CeLLS
While most studies have focused on the allo-reactive T cell in 
tolerance induction, the roles of allo-reactive B cells are largely 
unknown. However, a subset of B cells known as B regulatory 
cells (Bregs) has been identified as a potent factor in immune 
homeostasis and autoimmunity, and they have been found to 
be involved with maintaining immune tolerance associated with 
Regulatory T cells (132, 133). Recent work is uncovering a pos-
sible role in immunomodulation, which first gained attention 
when mice, deplete of B cells, were shown to develop a severe form 
of experimental autoimmune encephalomyelitis (EAE) (134). 
Further studies demonstrated similar findings in mouse models of 
autoimmune disorders such as collagen induced arthritis, ulcera-
tive colitis, and allergy (135–138). In 2007, investigators at MGH 
(139) reported to achieve tolerance in a heart transplant mouse 
model. They first established B-cell dependent allo-reactive tol-
erance using anti-CD45RB antibody. The phenomenon required 
the interaction of costimulation molecules on B cells with T cells, 
which were CD40+ and CD80/86+. They also reported in islet 
allograft models that mice treated with anti-CD45RB antibody 
plus anti-T cells immunoglobulin domain and mucin domain-1 
(anti-TIM-1) antibody were induced allo-reactive tolerance via 
an IL-10 dependent pathway (140). In addition, they recently 
showed that the Breg response was associated with Treg induc-
tion mediated by TGF-beta (141). A second group at University 
of Pittsburgh has indicated that TIM-1, which is an important 
marker for IL-10+ Bregs (induced by TIM-1 ligation), plays a 
critical role in regulation the immune response (142). A third 
group in Wisconsin has shown in an acute EAE mouse model 
deficient in B cells led to a delay in the emergence of FoxP3+ 
expression Regulatory T cells and the expression of IL-10 in the 
CNS. This was normalized by reconstitution with B cells, but 
was not normalized when reconstituted with B7 deficient B cells. 
The above work highlights a possible role for B cell dependent 
Treg expansion via B7 (143). Cell-to-cell contact has also been 
shown to contribute to B cell-dependent immunosuppression 
(144, 145). A recent study showed that coculture of purified 
Bregs was shown to suppress the proliferation of CD4+ T cells. 
Furthermore, Bregs coculture with Regulatory T cells led to the 
upregulation of FoxP3 and CTLA4 in Regulatory T cells (144). 
This evidence has led to the suggestion that Breg therapy may 
have an indirect role in immune tolerance therapy via ex vivo 
Treg expansion (133).
An immunoregulatory role for B cells has also been 
suggested in human diseases based on findings in patients 
with autoimmune diseases such as multiple sclerosis, lupus, 
rheumatoid arthritis, and even cancer (146–149). Numerous 
studies have begun to suggest that B cells also play an integral 
part in inducing immune tolerance in transplant patients (141, 
150–154). Although there are no studies to date regarding B cell 
therapy in humans, this technique has been quite successful in 
animal models of autoimmune diseases. Particularly exciting is 
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a model that has been developed in which polyclonal B cells are 
transduced with a retrovirus encoding specific antigens (155). 
Using this model, genetically modified B cells were able to 
inhibit autoimmune diseases such as uveitis, multiple sclerosis, 
type 1 diabetes, and rheumatoid arthritis in mouse models (19, 
156–160). These genetically engineered B cells were also shown 
to be capable of inducing the proliferation of FoxP3+ CD4+ 
Regulatory T cells (161). Furthermore, another group was able 
to show that reconstitution with similarly engineered B cells 
in  vivo protected against EAE in mice (162). Taken together, 
the success of B cell therapy for immunosuppression in animal 
models, and the established immunomodulatory role in humans 
suggests that the possibility of B cell-based cellular therapies 
for immune tolerance induction in humans is not out of the 
question.
OTHeR CeLL TYPeS
The above discussion is by no means complete. There are addi-
tional cell types which not included here which may be worthy 
of mention, such as apoptotic cells (163). Apoptotic cell-based 
therapies may improve graft survival and inflammatory diseases. 
Perhaps most excitingly, apoptotic cells may also be effective for 
the treatment of GVHD (163–165).
SYNTHeSiS OF THe DATA
Here, we have presented a number of different cell types, which 
contribute to tolerance induction. However, the presented data 
should be approached carefully. Indeed, mesenchymal stem cells 
or myeloid precursors (and/or MDSCs), which are present in the 
bone marrow may be involved in tolerance induction by cotrans-
plantation of bone marrow and a solid organ. The same is true 
for facilitating cells. However, cell therapies based on regulatory 
T  cells, B cells (Breg), dendritic cells, or macrophages emerge 
from their immunomodulatory properties rather than their sole 
presence in the bone marrow graft. Conversely, apoptotic cell-
based therapies (i.e., administration of donor apoptotic cells) 
or facilitating cells may account for tolerance induction after 
cotransplantation of bone marrow and solid organ. As such, the 
notion of tolerance inducing versus tolerance facilitation may 
require further discussion.
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